The natriuretic and diuretic effects of urodilatin in cirrhosis patients with severe sodium retention

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN36020026

Enrollment

Registered

2007-01-03

Start date

1999-01-28

Completion date

Unknown

Last updated

2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decompensated liver cirrhosis. Digestive System Diseases of the liver

Interventions

Comparison of 90 minutes intravenous (i.v.) infusion of synthetic urodilatin with placebo: 1. Urodilatin was dissolved in isotonic saline and the infusion dose was 20 ng/kg/min. Infusi

Eligibility

Inclusion criteria

Inclusion criteria: 1. Presence of cirrhosis in a liver biopsy 2. Anamnestic, clinical and laboratory evidence of cirrhosis including ascites (verified by ultrasound), oesophagogastric varices (verified by gastroscopy), hypoalbuminemia and reduced prothrombin index 3. A 24 hour urine sodium excretion less than 60 mmol 4. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Primary kidney disease (s-creatinine more than 200 mmol/L) 2. Congestive heart failure 3. Diabetes 4. Haemoglobin less than 6.0 mmol/L 5. A history of bladder dysfunction

Design outcomes

Primary

Measure	Time frame
The renal effects of Urodilatin were investigated in a clearance study. Primary outcomes were: 1. Urine flow rate 2. Urine sodium excretion rate 3. Plasma cyclic Guanosine 3',5'-MonoPhosphate (GMP)	—

Secondary

Measure	Time frame
1. Systemic blood pressure 2. The plasma hormones renin, angiotensin II and aldosterone	—

Countries

Denmark

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026